VCYT Insider Trading

Insider Ownership Percentage: 1.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,810,829.26

Veracyte Insider Trading History Chart

This chart shows the insider buying and selling history at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$426ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M$0$2MTotal Insider BuyingTotal Insider Selling

Veracyte Share Price & Price History

Current Price: $30.12
Price Change: Price Decrease of -0.98 (-3.15%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for VCYT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$30.12Closing price on 03/28/25:

SEC Filings (Institutional Ownership Changes) for Veracyte (NASDAQ:VCYT)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at VCYT by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$242Mbought$221MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
Veracyte logo
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Read More on Veracyte

Today's Range

Now: $30.12
Low: $29.65
High: $31.07

50 Day Range

MA: $37.57
Low: $30.12
High: $46.14

52 Week Range

Now: $30.12
Low: $18.61
High: $47.32

Volume

710,014 shs

Average Volume

835,914 shs

Market Capitalization

$2.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

Who are the company insiders with the largest holdings of Veracyte?

Veracyte's top insider shareholders include:
  1. Rebecca Chambers (CFO)
  2. John Leite (Insider)
  3. Evan/ Fa Jones (Director)
  4. Bonnie H Anderson (Director)
  5. Jonathan Wygant (CAO)
  6. Karin Eastham (Director)
  7. John L Bishop (Director)
  8. Muna Bhanji (Director)
  9. Jens Holstein (Director)
Learn More about top insider investors at Veracyte.

Who are the major institutional investors of Veracyte?

Veracyte's top institutional investors include:
  1. Vanguard Group Inc. — 10.60%
  2. Artisan Partners Limited Partnership — 8.52%
  3. ARK Investment Management LLC — 5.42%
  4. Wellington Management Group LLP — 5.24%
  5. ArrowMark Colorado Holdings LLC — 3.97%
  6. Dimensional Fund Advisors LP — 3.72%
Learn More about top institutional investors of Veracyte stock.

Which major investors are selling Veracyte stock?

In the last quarter, VCYT stock was sold by these institutional investors:
  1. Champlain Investment Partners LLC
  2. Bank of America Corp DE
  3. ARK Investment Management LLC
  4. ExodusPoint Capital Management LP
  5. Casdin Capital LLC
  6. Man Group plc
  7. Granahan Investment Management LLC
  8. Sumitomo Mitsui Trust Group Inc.
In the previous year, company insiders that have sold Veracyte company stock include:
  1. Rebecca Chambers (CFO)
  2. John Leite (Insider)
  3. Evan/ Fa Jones (Director)
  4. Bonnie H Anderson (Director)
  5. Jonathan Wygant (CAO)
  6. Karin Eastham (Director)
  7. John L Bishop (Director)
Learn More investors selling Veracyte stock.

Which major investors are buying Veracyte stock?

During the last quarter, VCYT stock was bought by institutional investors including:
  1. Artisan Partners Limited Partnership
  2. Marshall Wace LLP
  3. Driehaus Capital Management LLC
  4. Point72 Asset Management L.P.
  5. Vanguard Group Inc.
  6. Jennison Associates LLC
  7. Loomis Sayles & Co. L P
  8. Arrowstreet Capital Limited Partnership